The New York Proton Center Appoints Christopher Panczner as CEO
Former SVP and Chief Legal Officer of Montefiore Medicine brings track record of improving NY healthcare through collaboration with other healthcare institutions.
New York, NY – June 30, 2025 – The New York Proton Center, the state’s first and only proton radiation therapy center, is proud to announce the appointment of Christopher Panczner as its new Chief Executive Officer, effective June 10, 2025. A visionary healthcare leader with over 25 years of experience, Panczner brings a proven track record of strategic innovation and a patient-first approach to advancing cancer care.
Panczner has been a driving force in shaping New York’s healthcare landscape, most notably through his leadership at Montefiore Einstein, where he oversaw the acquisition and integration of eleven hospitals and the Albert Einstein College of Medicine and forged transformative partnerships that enhanced care delivery across the region. These partnerships included acquisition of financially distressed community hospitals serving medically underserved populations. By working with New York State and creditors, the Montefiore Einstein system ensured continuation of vital healthcare services in the community, while bringing enhanced clinical coordination and improving the quality of care.
Through his leadership at Montefiore Einstein and as a member of the NYPC Board of Directors since 2010, Panczner was critical in establishing the New York Proton Center and its unique collaboration with Memorial Sloan Kettering Cancer Center, Montefiore Health System, Mount Sinai Health System, and private equity partners to bring proton therapy to New York.
Panczner’s leadership in creating international clinical and research affiliations and restructuring Montefiore Einstein’s governance to align with best practices underscores his collaborative approach. His patient-centric vision ensures that every decision prioritizes innovative, compassionate care, improving outcomes and access for patients battling cancer.
“Chris’s strategic leadership, ability to build consensus, and unwavering commitment to patients make him the ideal leader to guide the New York Proton Center into its next phase of growth,” said Jonathan Weinbach, outgoing Chief Executive Officer. “His longstanding and deep connection to our mission and proven ability to drive impactful partnerships will strengthen our position as a global leader in proton therapy treatment and research.”
Panczner’s appointment signals an exciting future for the New York Proton Center, with plans to expand access to proton therapy, deepen collaborations with leading medical institutions, and continue delivering life-changing care to patients across New York and beyond.
About the New York Proton Center
The New York Proton Center (NYPC) is creating the gold standard for proton therapy, giving new hope to patients living with cancer. The NYPC is advancing new and better ways to fight cancer with proton therapy, a highly targeted form of radiation therapy with fewer treatment-related complications. In partnership with leading academic medical centers: Memorial Sloan Kettering Cancer Center, Montefiore Health System, and Mount Sinai Health System, NYPC is the only proton center in the state of New York, attracting patients from around the country and the world. Through impactful clinical trials and game-changing clinical research, NYPC’s internationally renowned clinical team continues to revolutionize cancer treatment while offering patients individualized, highly skilled and compassionate care.